RE:RE:Another biotech in Nash “While the biotech studied the drug in NASH “as a model disease” in context of fibrosis and inflammation, the chief executive noted that running NASH trials, especially pivotal ones, can get very costly. “We’d love to be able to get back to it, but from an economics viewpoint, financial viewpoint, it’s sort of let’s go for the orphan diseases first,” Pfost added, noting a possibility of a future partnership to tackle the disease.”
Fibrosis startup touts mid-stage NASH trial as it moves sole candidate forward – Endpoints News
https://seekingalpha.com/pr/19069005-chemomab-reports-top-line-results-from-cmminus-101-phase-2a-liver-fibrosis-biomarker-trial-in
Based on the price action it seems like some investors were disappointed due to the fact the trial is “parked”!
In terms of science the results from their phase 2 trial were from only 23 patients confirming safety and reduction of fibrosis based on FibroScan and levels of bio markers, I can’t find anything about the NAS score either.
THTX’s NASH asset is far more valuable than this tiny trial and in my opinion although some analysts have priced in both NASH and oncology in their reports the market hasn’t!! Again their NASH and oncology assets are not worthless unless they throw away the entire sort1 project and NASH, so far they haven’t but investors are not convinced, an issue which has to be addressed.